Healthcare entity
All 3 tracked stories fall under one category: market-trends. Of the tracked stories, 3 of 3 also mention Lantheus Holdings, the most common co-covered peer. Source depth averages 6 original sources per story, versus 4.4 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: market-trends. Of the tracked stories, 3 of 3 also mention Lantheus Holdings, the most common co-covered peer. Source depth averages 6 original sources per story, versus 4.4 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.7 for that window. This profile follows 3 Healthcare stories mentioning Heron Therapeutics across the period from February 25, 2026 to February 26, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 72 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Heron Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
Source: Seeking Alpha · Seeking Alpha
Delcath Systems, Lantheus Holdings, Butterfly Network, and Heron Therapeutics are preparing to report Q4 2025 earnings, marking a critical test for commercial-stage medical innovators. Investors are laser-focused on the adoption rates of flagship products like HEPZATO KIT and PYLARIFY as these companies navigate a complex reimbursement environment.
Source: Seeking Alpha · Seeking Alpha
Heron Therapeutics is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
